Skip to main content
Thank you for visiting nature.com. You are using a browser version
with limited support for CSS. To obtain the best experience, we
recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to
ensure continued support, we are displaying the site without styles
and JavaScript.
Advertisement
[image]
[image]
•  View all journals
•  
Search
•  Log in
•  Content Explore content
•  About the journal
•  Publish with us
•  Subscribe
•  Sign up for alerts
•  RSS feed
1. nature 
2. bone marrow transplantation 
3. original article 
4. article
Show authors
•  Original Article
•  Published: 03 December 2012


Post-Transplant Events
Bronchiolitis obliterans
syndrome after allogeneic
hematopoietic SCT: phenotypes
and prognosis
•  A Bergeron
1,
•  C Godet2,
•  S Chevret3,
•  G Lorillon1,
•  R Peffault de Latour4,
•  T de Revel5,
•  M Robin4,
•  P Ribaud4,
•  G Socié4 &
•  …
•  A Tazi1 
Bone Marrow Transplantation volume 48, pages 819–824 (2013)Cite
this article
•  4064 Accesses
•  88 Citations
•  2 Altmetric
•  Metrics details
Subjects
•  Bone marrow transplantation
•  Laboratory techniques and procedures
•  Prognosis
•  Respiratory tract diseases


Abstract
Bronchiolitis obliterans syndrome (BOS) after allogeneic
hematopoietic SCT (HSCT) is recognized as a new-onset obstructive
lung defect (OLD) in pulmonary function testing and is related to
pulmonary chronic GVHD. Little is known about the different
phenotypes of patients with BOS and their outcomes. We reviewed
the data of all allogeneic HSCT recipients referred to our pulmonary
department for a non-infectious bronchial disease between 1999
and 2010. We identified 103 patients (BOS (n=77), asthma (n=11)
and chronic bronchitis (n=15)). In patients with BOS, we identified
two functional phenotypes: a typical OLD, that is, forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7
(n=53), and an atypical OLD with a concomitant decrease in the
FEV1 <80% and FVC <80% predicted with a normal total lung
capacity (n=24). The typical OLD was characterized by more
severe FEV1 and fewer centrilobular nodules on the computed
tomography scan. The FEV1 was not significantly affected during
the follow-up, regardless of the phenotype. In addition to acute and
extensive chronic GVHD, only the occurrence of BOS soon after
transplantation and the intentional treatment of BOS with steroids
were associated with a poor survival. The determination of patient
subgroups should be explored to improve the management of this
condition.
 Access through your institution
Buy or subscribe
This is a preview of subscription content, access via your institution
Access options
 Access through your institution
Subscribe to this journal
Receive 12 print issues and online access


$259.00 per year
only $21.58 per issue
Learn more
Buy this article
•  Purchase on SpringerLink
•  Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during
checkout
Additional access options:
•  Log in
•  Learn about institutional subscriptions
•  Read our FAQs
•  Contact customer support
Figure 1
[image]
Figure 2
[image]
Similar content being viewed by others
[image]
Clinical risk factors and prognostic model for patients
with bronchiolitis obliterans syndrome after
hematopoietic stem cell transplantation
Article 27 November 2023
[image]


Evaluation of risk for bronchiolitis obliterans
syndrome after allogeneic hematopoietic cell
transplantation with myeloablative conditioning
regimens
Article Open access 27 September 2024
[image]
Late-onset pulmonary complications following
allogeneic hematopoietic cell transplantation in
pediatric patients: a prospective multicenter study
Article 07 March 2024
References
1. Bergeron A, Chevret S, Chagnon K, Petropoulou A, Robin M,
Desseaux K et al. Prospective evaluation of the incidence, risk
factors and clinical outcome of late onset non infectious
pulmonary complications after allogeneic hematopoietic stem
cell transplantation. Am J Respir Crit Care Med 2011; 183
Abstract 4667.
Google Scholar 
2. Afessa B, Peters SG . Chronic lung disease after hematopoietic
stem cell transplantation. Clin Chest Med 2005; 26: 571–586.
Article  Google Scholar 
3. Au BK, Au MA, Chien JW . Bronchiolitis obliterans syndrome
epidemiology after allogeneic hematopoietic cell
transplantation. Biol Blood Marrow Transplant 2011; 17:
1072–1078.
Article  Google Scholar 
4. Soubani AO, Uberti JP . Bronchiolitis obliterans following
haematopoietic stem cell transplantation. Eur Respir J 2007;


29: 1007–1019.
Article  CAS  Google Scholar 
5. Filipovich AH, Weisdorf D, Pavletic S, Socié G, Wingard JR,
Lee SJ et al. National Institutes of Health consensus
development project on criteria for clinical trials in chronic
graft-versus-host disease: I. Diagnosis and staging working
group report. Biol Blood Marrow Transplant 2005; 11: 945–
956.
Article  Google Scholar 
6. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F,
Casaburi R et al. Interpretative strategies for lung function
tests. Eur Respir J 2005; 26: 948–968.
Article  CAS  Google Scholar 
7. Williams KM, Chien JW, Gladwin MT, Pavletic SZ .
Bronchiolitis obliterans after allogeneic hematopoietic stem
cell transplantation. Jama 2009; 302: 306–314.
Article  CAS  Google Scholar 
8. Chien JW, Duncan S, Williams KM, Pavletic SZ . Bronchiolitis
obliterans syndrome after allogeneic hematopoietic stem cell
transplantation-an increasingly recognized manifestation of
chronic graft-versus-host disease. Biol Blood Marrow
Transplant 2010; 16: S106–S114.
Article  Google Scholar 
9. Standardized lung function testing. Official statement of the
European Respiratory Society. Eur Respir J Suppl 1993; 16: 1–
100.
Google Scholar 
10. Gail M, Simon R . Testing for qualitative interactions between
treatment effects and patient subsets. Biometrics 1985; 41:
361–372.


Article  CAS  Google Scholar 
11. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ . Bronchiolitis
obliterans in chronic graft-versus-host disease: analysis of risk
factors and treatment outcomes. Biol Blood Marrow Transplant
2003; 9: 657–666.
Article  Google Scholar 
12. Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR,
Nichols WG et al. Airflow obstruction after myeloablative
allogeneic hematopoietic stem cell transplantation. Am J
Respir Crit Care Med 2003; 168: 208–214.
Article  Google Scholar 
13. Philit F, Wiesendanger T, Archimbaud E, Mornex JF, Brune J,
Cordier JF . Post-transplant obstructive lung disease
("bronchiolitis obliterans"): a clinical comparative study of
bone marrow and lung transplant patients. Eur Respir J 1995;
8: 551–558.
CAS  PubMed  Google Scholar 
14. Chan CK, Hyland RH, Hutcheon MA, Minden MD, Alexander
MA, Kossakowska AE et al. Small-airways disease in recipients
of allogeneic bone marrow transplants. An analysis of 11
cases and a review of the literature. Medicine 1987; 66: 327–
340.
Article  CAS  Google Scholar 
15. Bergeron A, Belle A, Chevret S, Ribaud P, Devergie A,
Esperou H et al. Combined inhaled steroids and
bronchodilatators in obstructive airway disease after
allogeneic stem cell transplantation. Bone Marrow Transplant
2007; 39: 547–553.
Article  CAS  Google Scholar 
16. Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV,
Eapen GA et al. Inhaled corticosteroids stabilize constrictive


bronchiolitis after hematopoietic stem cell transplantation.
Bone Marrow Transplant 2008; 41: 63–67.
Article  CAS  Google Scholar 
17. Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M,
Al Mobeireek A et al. Azithromycin in bronchiolitis obliterans
complicating bone marrow transplantation: a preliminary
study. Eur Respir J 2005; 25: 490–493.
Article  CAS  Google Scholar 
18. Or R, Gesundheit B, Resnick I, Bitan M, Avraham A, Avgil M
et al. Sparing effect by montelukast treatment for chronic
graft versus host disease: a pilot study. Transplantation 2007;
83: 577–581.
Article  Google Scholar 
19. Norman BC, Jacobsohn DA, Williams KM, Au BK, Au MA, Lee
SJ et al. Fluticasone, azithromycin and montelukast therapy in
reducing corticosteroid exposure in bronchiolitis obliterans
syndrome after allogeneic hematopoietic SCT: a case series of
eight patients. Bone Marrow Transplant 2011; 46: 1369–1373.
Article  CAS  Google Scholar 
20. Agosti JM, Sprenger JD, Lum LG, Witherspoon RP, Fisher LD,
Storb R et al. Transfer of allergen-specific IgE-mediated
hypersensitivity with allogeneic bone marrow
transplantation. N Engl J Med 1988; 319: 1623–1628.
Article  CAS  Google Scholar 
Download references
Acknowledgements
We thank Elisabeth Savariau and Robin Nancel for their excellent
technical assistance.


Author information
Authors and Affiliations
1. Université Paris Diderot, Sorbonne Cité, Service de
Pneumologie, AP-HP, Hôpital Saint Louis, Paris, France
A Bergeron, G Lorillon & A Tazi
2. Service de Maladies Infectieuses et de Médecine Interne, CHU
Poitiers, France
C Godet
3. Département de Biostatistique et Informatique médicale,
UMR-S717 INSERM, Université Paris Diderot, Sorbonne Cité,
AP-HP, Hôpital Saint Louis, Paris, France
S Chevret
4. Université Paris Diderot, Sorbonne Cité, Hématologie-Greffe,
AP-HP, Hôpital Saint-Louis, Paris, France
R Peffault de Latour, M Robin, P Ribaud & G Socié
5. Service d'Hématologie, Hôpital d'instruction des armées
Percy, Clamart, France
T de Revel
Authors
1. A Bergeron
View author publications
Search author on:PubMed Google Scholar
2. C Godet
View author publications
Search author on:PubMed Google Scholar


3. S Chevret
View author publications
Search author on:PubMed Google Scholar
4. G Lorillon
View author publications
Search author on:PubMed Google Scholar
5. R Peffault de Latour
View author publications
Search author on:PubMed Google Scholar
6. T de Revel
View author publications
Search author on:PubMed Google Scholar
7. M Robin
View author publications
Search author on:PubMed Google Scholar
8. P Ribaud
View author publications
Search author on:PubMed Google Scholar
9. G Socié
View author publications
Search author on:PubMed Google Scholar
10. A Tazi
View author publications
Search author on:PubMed Google Scholar
Corresponding author


Correspondence to A Bergeron.
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
Reprints and permissions
About this article
Cite this article
Bergeron, A., Godet, C., Chevret, S. et al. Bronchiolitis obliterans
syndrome after allogeneic hematopoietic SCT: phenotypes and
prognosis. Bone Marrow Transplant 48, 819–824 (2013). https://
doi.org/10.1038/bmt.2012.241
Download citation
•  Received: 31 January 2012
•  Revised: 31 October 2012
•  Accepted: 31 October 2012
•  Published: 03 December 2012
•  Issue date: June 2013
•  DOI: https://doi.org/10.1038/bmt.2012.241
Share this article


Anyone you share the following link with will be able to read this
content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy shareable link to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative
Keywords
•  bronchiolitis obliterans
•  pulmonary function testing
•  allogeneic hematopoietic SCT
•  prognostic factors
This article is cited by
•  Late-onset pulmonary complications following
allogeneic hematopoietic cell transplantation in
pediatric patients: a prospective multicenter
study
○  Véronique Houdouin
○  Jean Christophe Dubus
○  Christophe Delclaux
Bone Marrow Transplantation (2024)
•  Mesenchymal stem cells reversibly de-
differentiate myofibroblasts to fibroblast-like
cells by inhibiting the TGF-β-SMAD2/3 pathway
○  Ruohao Xu
○  Miao Wu


○  Jianyu Weng
Molecular Medicine (2023)
•  Interstitial lung diseases after hematopoietic
stem cell transplantation: New pattern of lung
chronic graft-versus-host disease?
○  Gabrielle Archer
○  Ingrid Berger
○  Anne Bergeron
Bone Marrow Transplantation (2023)
•  Clinical risk factors and prognostic model for
patients with bronchiolitis obliterans syndrome
after hematopoietic stem cell transplantation
○  Qiu-Sha Huang
○  Tian-Xiao Han
○  Xiao-Hui Zhang
Bone Marrow Transplantation (2023)
•  The safety and tolerability of pirfenidone for
bronchiolitis obliterans syndrome after
hematopoietic cell transplant (STOP-BOS) trial
○  Efthymia Iliana Matthaiou
○  Husham Sharifi
○  Joe L. Hsu
Bone Marrow Transplantation (2022)
 Access through your institution
Buy or subscribe
Advertisement


[image]
Explore content
•  Research articles
•  Reviews & Analysis
•  News & Comment
•  Current issue
•  Collections
•  Follow us on Twitter
•  Subscribe
•  Sign up for alerts
•  RSS feed
About the journal
•  Journal Information
•  About the Editors
•  Contact
•  For Advertisers
•  Subscribe
•  Open Access Fees and Funding
Publish with us
•  For Authors and Referees
•  Language editing services
•  Open access funding
•  Submit manuscript
Search


Search articles by subject, keyword or author
Show results from All journals This journal
Search
Advanced search
Quick links
•  Explore articles by subject
•  Find a job
•  Guide to authors
•  Editorial policies
Bone Marrow Transplantation (Bone Marrow Transplant)
ISSN 1476-5365 (online)
ISSN 0268-3369 (print)
nature.com sitemap
About Nature Portfolio
•  About us
•  Press releases
•  Press office
•  Contact us
Discover content
•  Journals A-Z
•  Articles by subject
•  protocols.io
•  Nature Index
Publishing policies
•  Nature portfolio policies
•  Open access


Author & Researcher services
•  Reprints & permissions
•  Research data
•  Language editing
•  Scientific editing
•  Nature Masterclasses
•  Research Solutions
Libraries & institutions
•  Librarian service & tools
•  Librarian portal
•  Open research
•  Recommend to library
Advertising & partnerships
•  Advertising
•  Partnerships & Services
•  Media kits
•  Branded content
Professional development
•  Nature Awards
•  Nature Careers
•  Nature Conferences
Regional websites
•  Nature Africa
•  Nature China
•  Nature India
•  Nature Japan
•  Nature Middle East
•  Privacy Policy
•  Use of cookies


•  Your privacy choices/Manage cookies
•  Legal notice
•  Accessibility statement
•  Terms & Conditions
•  Your US state privacy rights
[image]
© 2025 Springer Nature Limited


[image]


